Since similar characteristics were also detected in another HNSCC clinical cohort (Kim et al., 2020), it was still unclear whether the HNSCC subtype with a higher TMB was susceptible to PD-1/PD-L1 therapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.